About the FAPWTR  


Familial amyloidotic polyneuropathy (FAP) is an autosomal, dominant, debilitating and fatal condition caused by a point mutation in transthyretin (TTR), one of the prealbumins. It affects the peripheral and autonomous nervous system as well as the heart, the kidneys and the intestinum.  As the liver is the main source of the circulating mutant form of TTR, orthotopic liver transplantation was introduced in 1990 as a radical and hopefully curative treatment for FAP.

In September 1993, the first Workshop in Liver Transplantation for Familial Amyloidotic Polyneuropathy (FAP) was held at Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden.
Consensus at this meeting was that orthotopic liver transplantation (OLT) for FAP is a worthwhile procedure that should continue.
There was also agreement among the participants that a register would be useful to promote collaboration and exchange of experiences between centers involved in this activity in order to compile data on patient survival and to determine the optimal time for transplantation.
At this initial meeting information was presented concerning 64 liver transplant recipients treated at 18 centers in 10 countries.

In October 1995, in Lissabon, Portugal, the FAPWTR was presented for the first time. By that time the registry comprised data on 146 patients from 25 different centers. Now, liver transplantation has become an established treatment for patients with transthyretin (TTR) systemic amyloidosis disorders and by December 31, 2019 a total of 2294 liver transplant recipients were recorded in the FAPWTR. The number of centers performing liver transplantation are 82 and they are found in 21 different countries all over the world.

Objectives of the FAPWTR:


Promote collaboration and exchange of experience


Monitor the international transplant activity 


Creation of  a database to optimize patient selection


Creation of a database to ensure adequate follow up post-transplant


Function as an investigative tool for reporting centers


Materials and methods:

All patient information is retrieved through report forms I and II, which are intended for reporting new patients and updating purposes respectively. We have included clinical parameters such as peripheral, cranial and autonomous neuropathy, extraneurological involvement and mean body mass index to try to evaluate if there is an improvement after OLT compared to pretransplant status as well as to establish their prognostic significance.
In recent years we have added questions about pharmacotherapy before and after liver transplantation.


Deadline for reporting:

All first time liver transplantations in FAP patients ought to be reported at a time close to the event or, by the latest, together with the yearly follow-up which has its deadline by 1st of March each year.



The FAP World Transplant Registry is sponsored by:

Industrial sponsors: